Want to dig deeper on Abbott Laboratories and thousands of companies?
Rapidly search an extensive universe of public and private content — earnings transcripts, company filings, equity research, trade journals, and more.
Request a Free TrialCompanies by industry
Aerospace & DefenseAutomobile ComponentsAutomobilesBanksBeveragesBiotechnologyBroadline RetailCapital MarketsChemicalsCommunications EquipmentConsumer FinanceConsumer Staples Distribution & RetailContainers & PackagingElectric UtilitiesElectronic Equipment, Instruments & ComponentsEnergy Equipment & ServicesEntertainmentFinancial ServicesFood ProductsGround TransportationHealth Care Equipment & SuppliesHealth Care Providers & ServicesHotels, Restaurants & LeisureHousehold DurablesHousehold ProductsIT ServicesIndustrial ConglomeratesIndustrial REITsInsuranceInteractive Media & ServicesLife Sciences Tools & ServicesMachineryMediaMetals & MiningMulti-UtilitiesOil, Gas & Consumable FuelsPersonal Care ProductsPharmaceuticalsSemiconductors & Semiconductor EquipmentSoftwareSpecialized REITsSpecialty RetailTechnology Hardware, Storage & PeripheralsTextiles, Apparel & Luxury GoodsTobaccoWireless Telecommunication Services
Abbott Laboratories Earnings - Analysis & Highlights for Q4 2024
Overview
PositivesNegativesOutlook
- Sales increased by 7% in Q4.
- The company achieved 9.5% sales growth, excluding COVID testing, and delivered 70 bps of gross margin profile improvement.
- The company launched Lingo in a restricted number of US cities and is expanding it nationally and internationally.
- The company generated $8.5 billion of operating cash flow, which was used to reinvest in the business, fund capacity expansions, repay debt, and return $5 billion to shareholders.
- The company expects to maintain a strong position in the mapping segment and all the consumables that come with it.
- Foreign exchange had an unfavorable YoY impact of 1.4% on Q4 sales.
- The company faced a little bit of friction due to a mismatch between manufacturing coming up online and the demand, especially in the US.
- The company faced a little bit of friction due to FX.
- The company faced a little bit of friction due to the mismatch between manufacturing coming up online and the demand, especially in the US.
- The company faced a little bit of friction due to the mismatch between manufacturing coming up online and the demand, especially in the US.
- The company is well positioned to deliver another year of strong growth in 2025.
- The company forecasts organic sales growth to be in the range of 7.5% to 8.5% and adjusted EPS to be in the range of $5.05 to $5.25, which reflects double-digit growth at the midpoint.
- The company forecasts its full-year 2025 adjusted operating margin profile to be in the range of 23.5% to 24% of sales, which reflects an improvement of 150 basis points versus the prior year at the midpoint of range.
- The company issued guidance for full-year adjusted EPS of $5.05 to $5.25, which reflects double-digit growth at the midpoint of the range and contemplates an adjusted EPS forecast of $1.05 to $1.09 for Q1.
- The company forecasts organic sales growth to be in the range of 7.5% to 8.5% for 2025.
Q&A Highlights from Abbott Laboratories Earnings Call Q4 2024
- Analyst asked about the key growth drivers and how to think about the different business segments on the top line and the components of the operating margin expansion down the P&L.
- Robert B. Ford, the CEO of Abbott Laboratories, explained that the company's growth drivers include a diversified healthcare business, strong product portfolios, and a focus on treatments, such as pharmaceuticals and med tech. He also highlighted the company's ability to benefit from accelerating markets and its strong product portfolios that are keeping up with or outperforming high-growth markets. In terms of margin drivers, Ford mentioned that the company has achieved gross margin expansion and has committed to a 70 basis point improvement in 2024, which it achieved. The company believes it can achieve another 80 basis points of improvement in 2025, driven by continued focus on gross margin improvement programs and mix. Additionally, the company has the opportunity to leverage the business and obtain spending leverage across the business. These factors, along with the company's ability to deal with FX and increased tax rates, contribute to the company's double-digit EPS growth.
- Robert B. Ford, the CEO of Abbott Laboratories, explained that the company's growth drivers include a diversified healthcare business, strong product portfolios, and a focus on treatments, such as pharmaceuticals and med tech. He also highlighted the company's ability to benefit from accelerating markets and its strong product portfolios that are keeping up with or outperforming high-growth markets. In terms of margin drivers, Ford mentioned that the company has achieved gross margin expansion and has committed to a 70 basis point improvement in 2024, which it achieved. The company believes it can achieve another 80 basis points of improvement in 2025, driven by continued focus on gross margin improvement programs and mix. Additionally, the company has the opportunity to leverage the business and obtain spending leverage across the business. These factors, along with the company's ability to deal with FX and increased tax rates, contribute to the company's double-digit EPS growth.
Related Companies:
